Back
Compare AU
Compare A200 vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Australia 200 ETF (A200) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
A200 | CURE | |
|---|---|---|
Popularity | Medium | Low |
Pearlers invested | 7,659 | 73 |
Median incremental investment | $1,039.00 | $674.27 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,631.92 | $2,349.80 |
Average age group | 26 - 35 | > 35 |
Key Summary
A200 | CURE | |
|---|---|---|
Strategy | BetaShares Australia 200 ETF (ASX: A200) seeks to track the performance of the Solactive Australia 200 index before account fees, expenses, and taxes. The index tracks the largest 200 companies on the Australian Securities Exchange (ASX). | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | SPI 200 FUTURES SEP26 (0 %) BHP GROUP LTD (11.44 %) COMMONWEALTH BANK OF AUSTRALIA (10.23 %) | Twist Bioscience Corp (1.73 %) Oruka Therapeutics Inc (1.57 %) Apogee Therapeutics Inc (1.53 %) |
Top 3 industries | Financials (33.65 %) Materials (17.69 %) Health Care (8.32 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | Australia (95.75 %) United States (2.80 %) New Zealand (0.55 %) | United States (96.62 %) United Kingdom of Great Britain and Northern Ireland (1.35 %) Switzerland (1.13 %) |
Management fee | 0.04 % | 0.45 % |
Key Summary
A200 | CURE | |
|---|---|---|
Issuer | BetaShares | Global X |
Tracking index | Solactive Australia 200 Index - AUD | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.04 % | 0.45 % |
Price | $151.78 | $76.50 |
Size | $10.950 billion | $49.167 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 4.10 % | 0.03 % |
Market | ASX | ASX |
First listed date | 08/05/2018 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
A200 | CURE | |
|---|---|---|
Popularity | Medium | Low |
Pearlers invested | 7,659 | 73 |
Median incremental investment | $1,039.00 | $674.27 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,631.92 | $2,349.80 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
A200 | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
A200 | CURE |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |